Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Dominari Holdings's share price for the quarter that ended in Dec. 2023 was $2.59. Dominari Holdings's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 5.93 Mil. Therefore, Dominari Holdings's market cap for the quarter that ended in Dec. 2023 was $15.37 Mil.
Dominari Holdings's quarterly market cap
declined
from Jun. 2023 ($15.38 Mil) to Sep. 2023 ($12.26 Mil) but then
increased
from Sep. 2023 ($12.26 Mil) to Dec. 2023 ($15.37 Mil).
Dominari Holdings's annual market cap
declined
from Dec. 2021 ($52.64 Mil) to Dec. 2022 ($16.46 Mil) and
declined
from Dec. 2022 ($16.46 Mil) to Dec. 2023 ($15.37 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Dominari Holdings's Enterprise Value for Today is $3.09 Mil.
Dominari Holdings Market Cap Historical Data
The historical data trend for Dominari Holdings's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Dominari Holdings's Market Cap
For the Biotechnology subindustry, Dominari Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dominari Holdings's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dominari Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Dominari Holdings's Market Cap falls into.
Dominari Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Dominari Holdings's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dominari Holdings (NAS:DOMH) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Dominari Holdings Market Cap Related Terms
Thank you for viewing the detailed overview of Dominari Holdings's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Dominari Holdings (Dominari Holdings) Business Description
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing a therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore, and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company is also developing an antiviral platform, in which the compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DOMH has been successfully added to your 